Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Pretax Income (Earnings)?

  Alexion Pharmaceuticals Inc ( ALXN ) |
2002 - 2021 (20 years)

Pretax Income (Earnings) is 
$1.3B (1Y +10.1% )

ALXN Stock Price & Pretax Income (Earnings)

Pretax Income (Earnings) for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Pretax Income (Earnings)

chevron_right 2021 $590.6M +7.3x *
( +11.2% / year avg)
chevron_left 2002 -$71.0M
vertical_align_top Peak $1.5B +13.3x *
vertical_align_bottom Bottom -$125.5M
arrow_drop_up # Up Years 13 13 of 20
years up.
arrow_drop_down # Down Years 7
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 2002 , or -4.84x faster than it's pretax income (earnings) over the same period.
  • If ALXN grows it's stock at the same rate as it's pretax income (earnings) (+11.2%/year) , it's stock price will grow +289% and hit $314.31 over the next 10 years.
  • ALXN's stock price has gone up 6 of the 13 years (+46%) it's pretax income (earnings) were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical Pretax Income (Earnings) Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Pretax Income (Earnings) YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $590 1.8% $108.72 -9.3%
    4/1/2020 $580 -62.4% $119.9 5.5%
    4/1/2019 $1,543 323.1% $113.68 -2.1%
    4/1/2018 $364 -35.1% $116.13 18.5%
    4/1/2017 $562 44.9% $98.03 -30.4%
    4/1/2016 $388 -38.3% $140.8 -21.9%
    4/1/2015 $628 -21.8% $180.37 2.0%
    4/1/2014 $804 62.4% $176.8 91.9%
    4/1/2013 $495 36.0% $92.14 -0.8%
    4/1/2012 $364 82.3% $92.86 88.2%
    4/1/2011 $199 56.9% $49.34 81.5%
    4/1/2010 $127 64.4% $27.18 44.4%
    4/1/2009 $77 615.4% $18.83 27.0%
    4/1/2008 $10 -109.1% $14.82 37.1%
    4/1/2007 $-119 3.6% $10.81 22.1%
    4/1/2006 $-115 -8.0% $8.86 63.5%
    4/1/2005 $-125 70.2% $5.42 -8.8%
    4/1/2004 $-73 -12.1% $5.94 80.8%
    4/1/2003 $-83 18.1% $3.29 -28.8%
    4/1/2002 $-71 - $4.62 -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Pretax income is a company's income after all operating expenses, including interest and depreciation, have been deducted from total sales or revenues, but before income taxes have been subtracted. Because pretax earnings exclude taxes, this measure enables the intrinsic profitability of companies to be compared across industries or geographic regions where corporate taxes differ. For instance, while U.S.-based corporations face the same tax rates at the federal level, they face different tax rates at the state level.

    For more detailed definitions, please see Investopedia.